Study Phase 3

A Double-blind, Placebo-controlled, Randomized Trial to Evaluate the Safety, Tolerability and Efficacy of CONCERTA® (Methylphenidate Hydrochloride) Augmentation of SSRI/SNRI Monotherapy in Adult Patients With Major Depressive Disorder.

Trial Information

Generic NameMethylphenidate HClProduct NameCONCERTA®Therapeutic AreaBehaviors and Mental DisordersEnrollment145% Female64.8%% White97.9%
Product ClassStimulants/ADHD/AnorexiantsSponsor Protocol Number42603MDD3001 (CON-CAN-3)Data PartnerJohnson & JohnsonCondition StudiedDepressive Disorder, MajorMean/Median Age (Years)43.8

Supporting Documentation

  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Analysis Datasets Available
  • Clinical Study Report Available


Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.